O	0	3	The
O	4	11	natural
O	12	19	history
O	20	23	and
O	24	33	prognosis
O	34	36	of
B-Disease	37	48	neovascular
I-Disease	49	52	age
I-Disease	52	53	-
I-Disease	53	60	related
I-Disease	61	68	macular
I-Disease	69	81	degeneration
O	81	82	:
O	83	84	a
O	85	95	systematic
O	96	102	review
O	103	105	of
O	106	109	the
O	110	120	literature
O	121	124	and
O	125	129	meta
O	129	130	-
O	130	138	analysis
O	138	139	.

O	141	143	To
O	144	152	describe
O	153	156	the
O	157	164	natural
O	165	172	history
O	173	176	and
O	177	188	progression
O	189	191	of
B-Symptom	192	198	visual
I-Symptom	199	203	loss
O	204	206	in
B-Anatomy	207	211	eyes
O	212	216	with
O	217	226	untreated
B-Disease	227	238	neovascular
I-Disease	239	242	age
I-Disease	242	243	-
I-Disease	243	250	related
I-Disease	251	258	macular
I-Disease	259	271	degeneration
O	272	273	(
B-Disease	273	276	AMD
O	276	277	)
O	277	278	.

O	279	289	Systematic
O	290	296	review
O	297	300	and
O	301	305	meta
O	305	306	-
O	306	314	analysis
O	314	315	.

O	316	320	Four
O	321	329	thousand
O	330	335	three
O	336	343	hundred
O	344	349	sixty
O	349	350	-
O	350	353	two
O	354	363	untreated
B-Disease	364	375	neovascular
I-Disease	376	379	AMD
O	380	388	patients
O	389	393	from
O	394	403	published
O	404	418	interventional
O	419	426	studies
O	426	427	.

O	428	429	A
O	430	440	systematic
O	441	447	review
O	448	450	of
O	451	454	the
O	455	465	literature
O	466	470	from
O	471	475	1980
O	476	478	to
O	479	485	August
O	486	490	2005
O	491	494	was
O	495	504	performed
O	504	505	.

O	506	513	Studies
O	514	523	reporting
O	524	531	disease
O	532	543	progression
O	544	552	outcomes
O	553	556	for
O	557	566	untreated
O	567	575	patients
O	576	580	with
B-Disease	581	592	neovascular
I-Disease	593	596	AMD
O	597	601	were
O	602	610	included
O	610	611	.

O	612	619	Outcome
O	620	628	measures
O	629	633	were
O	634	644	summarized
O	645	650	using
O	651	657	simple
O	658	664	counts
O	665	668	and
O	669	674	means
O	674	675	.

O	676	682	Random
O	683	690	effects
O	691	695	meta
O	695	696	-
O	696	704	analyses
O	705	709	were
O	710	719	conducted
O	720	723	and
O	724	729	tests
O	730	732	of
O	733	746	heterogeneity
O	747	751	were
O	752	761	performed
O	762	767	where
O	768	779	appropriate
O	779	780	.

O	781	788	Changes
O	789	791	in
B-Symptom	792	798	visual
I-Symptom	799	805	acuity
I-Symptom	806	807	(
I-Symptom	807	809	VA
I-Symptom	809	810	)
I-Symptom	811	815	loss
O	815	816	,
O	817	828	development
O	829	831	of
O	832	845	comorbidities
O	845	846	,
O	847	850	and
B-Characteristic	851	857	fellow
I-Characteristic	858	861	eye
I-Characteristic	862	873	involvement
O	873	874	.

O	875	880	Fifty
O	880	881	-
O	881	886	three
O	887	894	primary
O	895	902	studies
O	903	907	were
O	908	916	included
O	916	917	.

O	918	924	Nearly
O	925	929	half
O	930	932	of
O	933	936	the
O	937	944	studies
O	945	946	(
O	946	948	28
O	948	949	)
O	950	954	were
O	955	965	randomized
O	966	974	clinical
O	975	981	trials
O	981	982	.

O	983	986	The
O	987	994	quality
O	995	997	of
O	998	1001	the
O	1002	1009	studies
O	1010	1013	was
O	1014	1018	high
O	1018	1019	,
O	1020	1024	with
O	1025	1029	over
O	1030	1032	80
O	1032	1033	%
O	1034	1043	providing
O	1044	1049	level
O	1050	1051	I
O	1052	1054	or
O	1055	1057	II
O	1058	1066	evidence
O	1066	1067	.

O	1068	1072	Mean
O	1073	1081	baseline
B-Characteristic	1082	1084	VA
O	1085	1090	among
O	1091	1096	study
O	1097	1105	patients
O	1106	1109	was
O	1110	1111	0
O	1111	1112	.
O	1112	1114	64
B-Characteristic	1115	1124	logarithm
I-Characteristic	1125	1127	of
I-Characteristic	1128	1131	the
I-Characteristic	1132	1139	minimum
I-Characteristic	1140	1145	angle
I-Characteristic	1146	1148	of
I-Characteristic	1149	1159	resolution
O	1160	1161	(
B-Characteristic	1161	1167	logMAR
O	1167	1168	)
O	1169	1170	(
O	1170	1183	approximately
O	1184	1186	20
O	1186	1187	/
O	1187	1189	87
B-Characteristic	1190	1197	Snellen
O	1197	1198	)
O	1198	1199	.

O	1200	1203	The
O	1204	1208	mean
B-Characteristic	1209	1211	VA
O	1212	1218	change
O	1219	1221	in
B-Characteristic	1222	1228	logMAR
O	1229	1239	progressed
O	1240	1244	from
O	1245	1246	0
O	1246	1247	.
O	1247	1248	1
O	1249	1250	(
O	1250	1251	1
O	1252	1256	line
O	1257	1261	lost
O	1261	1262	)
O	1263	1265	at
O	1266	1267	3
O	1268	1274	months
O	1275	1277	to
O	1278	1279	0
O	1279	1280	.
O	1280	1281	3
O	1282	1283	(
O	1283	1284	2
O	1284	1285	.
O	1285	1286	7
O	1287	1292	lines
O	1293	1297	lost
O	1297	1298	)
O	1299	1304	after
O	1305	1307	12
O	1308	1314	months
O	1315	1318	and
O	1319	1320	0
O	1320	1321	.
O	1321	1322	4
O	1323	1324	(
O	1324	1325	4
O	1326	1331	lines
O	1332	1336	lost
O	1336	1337	)
O	1338	1343	after
O	1344	1346	24
O	1347	1353	months
O	1353	1354	.

O	1355	1358	The
O	1359	1369	proportion
O	1370	1372	of
O	1373	1381	patients
O	1382	1385	who
O	1386	1395	developed
B-Symptom	1396	1402	severe
I-Symptom	1403	1409	vision
I-Symptom	1410	1414	loss
O	1415	1416	(
O	1417	1418	>
O	1419	1420	6
O	1421	1426	lines
O	1426	1427	)
O	1428	1432	from
O	1433	1441	baseline
O	1442	1451	increased
O	1452	1456	from
O	1457	1459	21
O	1459	1460	.
O	1460	1461	3
O	1461	1462	%
O	1463	1465	at
O	1466	1467	6
O	1468	1474	months
O	1475	1477	to
O	1478	1480	41
O	1480	1481	.
O	1481	1482	9
O	1482	1483	%
O	1484	1486	by
O	1487	1488	3
O	1489	1494	years
O	1494	1495	.

O	1496	1499	The
O	1500	1510	proportion
O	1511	1513	of
O	1514	1522	patients
O	1523	1527	with
B-Symptom	1528	1530	VA
I-Symptom	1531	1536	worse
I-Symptom	1537	1541	than
I-Symptom	1542	1548	logMAR
I-Symptom	1549	1550	1
I-Symptom	1550	1551	.
I-Symptom	1551	1552	0
I-Symptom	1553	1554	(
I-Symptom	1554	1556	20
I-Symptom	1556	1557	/
I-Symptom	1557	1560	200
I-Symptom	1561	1568	Snellen
I-Symptom	1568	1569	)
O	1570	1579	increased
O	1580	1584	from
O	1585	1587	19
O	1587	1588	.
O	1588	1589	7
O	1589	1590	%
O	1591	1593	at
O	1594	1602	baseline
O	1603	1605	to
O	1606	1608	75
O	1608	1609	.
O	1609	1610	7
O	1610	1611	%
O	1612	1614	by
O	1615	1616	3
O	1617	1622	years
O	1622	1623	.

B-Disease	1624	1635	Neovascular
I-Disease	1636	1639	AMD
O	1640	1649	developed
O	1650	1652	in
O	1653	1656	the
O	1657	1663	fellow
B-Anatomy	1664	1667	eye
O	1668	1670	in
O	1671	1673	12
O	1673	1674	.
O	1674	1675	2
O	1675	1676	%
O	1677	1679	of
O	1680	1688	patients
O	1689	1691	by
O	1692	1694	12
O	1695	1701	months
O	1702	1705	and
O	1706	1708	in
O	1709	1711	26
O	1711	1712	.
O	1712	1713	8
O	1713	1714	%
O	1715	1717	by
O	1718	1719	4
O	1720	1725	years
O	1725	1726	.

O	1727	1731	Meta
O	1731	1732	-
O	1732	1740	analyses
O	1741	1743	of
O	1744	1750	vision
O	1751	1758	outcome
O	1759	1761	by
O	1762	1769	subtype
O	1770	1772	of
B-Disease	1773	1784	neovascular
I-Disease	1785	1788	AMD
O	1789	1793	were
O	1794	1797	not
O	1798	1806	possible
O	1806	1807	.

O	1808	1809	A
B-Symptom	1810	1818	doubling
I-Symptom	1819	1821	of
I-Symptom	1822	1825	the
I-Symptom	1826	1832	visual
I-Symptom	1833	1838	angle
I-Symptom	1839	1841	of
I-Symptom	1842	1852	presenting
I-Symptom	1853	1855	VA
O	1856	1859	may
O	1860	1862	be
O	1863	1871	expected
O	1872	1874	to
O	1875	1880	occur
O	1881	1883	in
O	1884	1887	the
O	1888	1892	year
O	1893	1898	after
O	1899	1906	initial
O	1907	1919	presentation
O	1920	1922	in
B-Anatomy	1923	1927	eyes
O	1928	1932	with
O	1933	1942	untreated
B-Disease	1943	1954	neovascular
I-Disease	1955	1958	AMD
O	1958	1959	.

O	1960	1962	No
O	1963	1974	conclusions
O	1975	1978	can
O	1979	1981	be
O	1982	1987	drawn
O	1988	1990	as
O	1991	1993	to
O	1994	1997	the
O	1998	2009	differences
O	2010	2012	in
O	2013	2018	rates
O	2019	2021	of
O	2022	2029	disease
O	2030	2041	progression
O	2042	2044	by
B-Disease	2045	2056	neovascular
I-Disease	2057	2060	AMD
O	2061	2068	subtype
O	2068	2069	.

O	2070	2073	The
O	2074	2083	diversity
O	2084	2086	of
O	2087	2096	reporting
O	2097	2104	formats
O	2104	2105	,
O	2106	2113	paucity
O	2114	2116	of
O	2117	2121	long
O	2121	2122	-
O	2122	2126	term
O	2127	2134	natural
O	2135	2142	history
O	2143	2147	data
O	2147	2148	,
O	2149	2152	and
O	2153	2166	heterogeneity
O	2167	2172	among
O	2173	2176	the
O	2177	2185	reported
O	2186	2194	clinical
O	2195	2202	studies
O	2203	2209	impose
O	2210	2216	limits
O	2217	2219	to
O	2220	2223	the
O	2224	2229	clear
O	2230	2243	understanding
O	2244	2246	of
O	2247	2251	long
O	2251	2252	-
O	2252	2256	term
O	2257	2266	prognosis
O	2267	2270	for
B-Characteristic	2271	2277	visual
I-Characteristic	2278	2286	function
O	2287	2289	in
B-Disease	2290	2301	neovascular
I-Disease	2302	2305	AMD
O	2305	2306	.
